Healthcare dealmaking hasn’t stopped — but the playbook is clearly evolving.
In a market defined by higher rates, tighter capital, and increased regulatory scrutiny, healthcare M&A is no longer just about finding the right asset — it’s about managing complexity after the deal closes
Healthcare dealmaking may be slower and more selective, but it’s far from stalled.
Healthcare dealmaking isn’t short on capital—or targets. What it is short on is certainty.